Bento, L, Gutiérrez, A, Martinez, C, Verdet, MCO, Sorribes, M, Caballero, AC, Peña, M, Pérez, A, Jiménez-Ubieto, A, Medina, L, Bastos-Oreiro, M, Caldas-González, PF, Navarro, B, Salcedo, I, Abrisqueta, P, Español, I, Cornago, J, Martín-Moro, F, García, L, Gómez, P, Varela, MR, Puente, M, Zanabili, J, Zudaire, T, Zeberio, I, del Campo, R, González, L, González, P, Blázquez, C, Rovira, J, Sitges, M, Franch-Sarto, M, Cabero, A, Mussetti, A, Montoro, J, Sampol, A, Sureda, A, Caballero, D, García-Sancho, AM. Autologous stem cell transplantation for relapsed/refractory large B-cell lymphoma: a multicenter GETH-TC/GELTAMO study. Blood Advances. 2025; 9(13)DOI:10.1182/bloodadvances.2024015415. PMID:40163764. IF:7.100(Q1/2D).

Rubio, MA, Cisa-Wieczorek, S, Mozos, A, Castellet, H, Bussaglia, E, Carricondo, M, Hernández-Alvarez, MI, Sierra, J, Nomdedéu, JF. SGK1 repression by WT1 may confer a survival advantage to leukemic cells under stress conditions. ANNALS OF HEMATOLOGY. 2025; 104(7)DOI:10.1007/s00277-025-06458-z. PMID:40613901. IF:2.400(Q2/5D).

Moreno, DF, Oriol, A, de la Rubia, J, Hernández, MT, Iñigo, MB, Palomera, L, de Arriba, F, González, Y, Teruel, AI, Pardo, JL, de la Guía, AL, Sampol, A, Ríos-Tamayo, R, Sureda, A, Gutiérrez, NC, Calasanz, MJ, Ramos, MLM, Mateos, MV, San Miguel, J, Lahuerta, JJ, Bladé, J, Rosiñol, L. Is t(11;14) Always aStandard-Risk Cytogenetic Abnormality? Results From GEM05MENOS65 and GEM2012 PETHEMA/GEM Trials. Clinical Lymphoma Myeloma & Leukemia. 2025; 25(7)DOI:10.1016/j.clml.2025.01.014. PMID:39955256. IF:2.700(Q2/4D).

Gagelmann, N, de Witte, M, Peczynski, C, Boreland, W, Broers, AEC, Jost, E, Kulagin, A, Esquirol, A, Sica, S, Kuball, J, Errico, G, Bethge, W, Maertens, J, Stölzel, F, Forcade, E, Collin, M, Parma, M, Choi, G, Kröger, N, Di Chio, MC, Finazzi, MC, Corral, LL, Rifón, J, Mussetti, A, Bloor, A, Ladetto, M, Schoemans, H, Penack, O, Moiseev, I, Peric, Z. Daratumumab for PRCA after HCT: study and practical considerations from the EBMT Transplant Complications Working Party. Blood Cancer Journal. 2025; 15(1)DOI:10.1038/s41408-025-01315-8. PMID:40467580. IF:11.600(Q1/1D).

Jiménez-Vicente, C, Arribas, I, Pomares, H, Ramil, G, Castaño-Diez, S, Pérez-Valencia, AI, Sturla, AL, López-Guerra, M, Martinez-Roca, A, Zugasti, I, Guijarro, F, Cortés-Bullich, A, Merchán, B, Triguero, A, Monge, I, Tuca, A, Oñate, G, Garrido, A, Sierra, J, Arnan, M, Esteve, J, Díaz-Beyá, M. Real-life outcome after failure to venetoclax and hypomethylating-based therapy for acute myeloid leukemia. HAEMATOLOGICA. 2025; 110(6)DOI:10.3324/haematol.2024.286589. PMID:39844754. IF:10.100(Q1/2D).

Jimenez-Vicente, C, Cardus, A, Castaño-Diez, S, Ramil, G, Garcia-Avila, S, Gomez-Perez, L, Esteban, D, Arribas, I, Sturla, AL, Lopez-Guerra, M, Martinez-Roca, A, Cortes-Bullich, A, Perez-Valencia, AI, Zugasti, I, Monge, I, Carcelero, E, Vall-Llovera, F, Vives, S, Sierra, J, Nomdedeu, J, Oñate, G, Garrido, A, Pratcorona, M, Pomares, H, Arnan, M, Guijarro, F, Diaz-Beya, M, Esteve, J. Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendations. Blood Cancer Journal. 2025; 15(1)DOI:10.1038/s41408-025-01298-6. PMID:40368916. IF:11.600(Q1/1D).

Sobas, MA, Turki, AT, Ramiro, AV, Hernández-Sánchez, A, Elicegui, JM, González, T, Melchor, RA, Abáigar, M, Tur, L, Dall'Olio, D, Sträng, E, Tettero, JM, Castellani, G, Benner, A, Doehner, K, Thiede, C, Metzeler, KH, Haferlach, T, Damm, F, Ayala, R, Martínez-López, J, Mills, KI, Sierra, J, Lehmann, S, Della Porta, MG, Mayer, J, Reinhardt, D, Medina, RV, Schulze-Rath, R, Barbus, M, Hernández-Rivas, JM, Huntly, BJP, Ossenkoppele, G, Döhner, H, Bullinger, L. Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance. HAEMATOLOGICA. 2025; 110(5)DOI:10.3324/haematol.2024.285805. PMID:39506894. IF:10.100(Q1/2D).

Lambert, N, Forte, F, El Moussaoui, M, Monseur, J, Raus, N, Polushin, A, Michonneau, D, Shultz, C, Hogan, WJ, Balaguer-Roselló, A, Gil-Perotín, S, Brijs, J, Chauvet, P, Gavriilaki, M, Carre, M, Dulamea, AO, Chalandon, Y, Salmenniemi, U, Duminuco, A, Ram, R, García-Cadenas, I, Porto, G, Nguyen, S, Smallbone, P, González-Vicent, M, Santoro, JD, Willems, E, Baron, F, Servais, S, Beguin, Y, Maquet, P, CNS GvHD Study Grp. CNS manifestations in acute and chronic graft-versus-host disease. BRAIN. 2025; 148(4)DOI:10.1093/brain/awae340. PMID:39442000. IF:11.700(Q1/1D).

Spyridonidis, A, Labopin, M, Savani, BP, Kulagin, A, Blaise, D, Broers, AEC, Sica, S, Raiola, AM, Vydra, J, Choi, G, Rovira, M, Kwon, M, Sanz, J, Itäla-Remes, M, von dem Borne, P, Esquirol, A, Koc, Y, Brissot, E, Nagler, A, Mohty, M, Ciceri, F. The impact of individual comorbidities in transplant recipients receiving post-transplant cyclophosphamide. BONE MARROW TRANSPLANTATION. 2025; 60(4)DOI:10.1038/s41409-025-02514-4. PMID:39910175. IF:5.200(Q1/1D).

Jiménez-Vicente, C, Esteve, J, Baile-González, M, Pérez-López, E, Calvo, CM, Aparicio, C, Ormategi, IO, Esquirol, A, Peña-Muñoz, F, Fernandez-Luis, S, Fernando, IH, González-Rodríguez, AP, López-García, A, López-Lorenzo, JL, Torrado, T, Marín, AJS, Fleytas, CA, García, L, Villar, S, Filaferro, S, Balsalobre, P, Cascón, MJP, Salas, MQ. Allo-HCT refined ELN 2022 risk classification: validation of the Adverse-Plus risk group in AML patients undergoing allogeneic hematopoietic cell transplantation within the Spanish Group for Hematopoietic Cell Transplantation (GETH-TC). Blood Cancer Journal. 2025; 15(1)DOI:10.1038/s41408-025-01223-x. PMID:40118819. IF:11.600(Q1/1D).

Navarro, S, Moukheiber, C, Sancho, SI, Guillén, MR, de Cerio, ALD, Sanges, C, Tanaka, T, Arnould, S, Briones, J, Dolstra, H, Hudecek, M, Choudhary, R, Schapitz, I, Juan, ME, Worel, N, Ammar, D, Luu, M, Mueller, M, Schroeder, B, Negre, H, Franz, P. Optimizing CAR-T treatment: A T2EVOLVE guide to raw and starting material selection. MOLECULAR THERAPY. 2025; 33(3)DOI:10.1016/j.ymthe.2024.11.017. PMID:39533710. IF:12.000(Q1/1D).

Escamilla-Gómez, V, Gutiérrez, VG, Alcalde-Mellado, P, Astibia-Mahillo, B, Chinea-Rodriguez, A, López-Corral, L, Acera-Gómez, M, Ochando, MKT, Borrego, AB, Pinedo, LG, Ripa, TZ, Vicent, MG, Benzaquén, A, García, II, Cantó, PA, Montoro, J, Martín-Domínguez, FM, Orti, G, Valcárcel, D, Benitez-Carabante, MI, Diaz-de-Heredia, C, Cañamero, E, Ferrá, C, García-Cadenas, I, Redondo, S, Sisinni, L, Perez-Martínez, A, Mussetti, A, Garcia-Mañó, L, Palomo-Moraleda, MD, González-Sierra, PA, Jurado, M, Perez-Simon, JA. Ruxolitinib in acute and chronic graft-versus-host disease: real life long-term experience in a multi-center study for adult and pediatric patients, on behalf of the GETH-TC. BONE MARROW TRANSPLANTATION. 2025; 60(3)DOI:10.1038/s41409-024-02483-0. PMID:39663471. IF:5.200(Q1/1D).

Sierro-Martinez, B, Escamilla-Gomez, V, Perez-Ortega, L, Guijarro-Albaladejo, B, Hernandez-Diaz, P, de la Rosa-garrido, M, Lara-Chica, M, Rodriguez-Gil, A, Reguera-Ortega, JL, Sanoja-Flores, L, Arribas-Arribas, B, Montiel-Aguilera, MA, Carmona, G, Robles, MJ, Caballero-Velazquez, T, Briones, J, Einsele, H, Hudecek, M, Perez-Simon, JA, Garcia-Guerrero, E. Next-generation BCMA-targeted chimeric antigen receptor CARTemis-1: the impact of manufacturing procedure on CAR T-cell features. CELLULAR ONCOLOGY. 2025; 48(1)DOI:10.1007/s13402-024-00984-0. PMID:39192092. IF:4.800(Q1/1D).

Oñate, G, Garrido, A, Arnan, M, Pomares, H, Alonso, E, Tormo, M, Diaz-Beya, M, Vives, S, Zamora, L, Sampol, A, Coll, R, Salamero, O, Cervera, M, Garcia, A, Vall-Llovera, F, Garcia-Avila, S, Bargay, J, Ortin, X, Iranzo, E, Guijarro, F, Pratcorona, M, Nomdedeu, JF, Esteve, J, Sierra, J. Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group. Blood Cancer Journal. 2025; 15(1)DOI:10.1038/s41408-024-01205-5. PMID:39799145. IF:11.600(Q1/1D).

Salas, MQ, Solano, MT, González, MB, Gómez, MA, Fox, L, Artigas, MDP, Santamaría, A, González, MDQ, Salinas, AS, Camacho, JMS, Alvaro, VI, Abdallahi-Lefdil, Z, Navascues, JC, Pardo, L, Fernández-Luis, S, Suárez, LPV, Villar, S, Beorlegui-Murillo, P, Esquirol, A, García, II, González, SR, Mussetti, A, Lavilla, E, Lopez-Marín, J, Filaferro, S, Cedillo, A, Bento, L, Sureda, A. Frailty assessment in adults undergoing allogeneic hematopoietic cell transplantation: insights from a multicenter GETH-TC study to optimize outcomes and care. Frontiers in Immunology. 2025; 15DOI:10.3389/fimmu.2024.1512154. PMID:39840039. IF:5.900(Q1/2D).

González-Gil, C, Morgades, M, Lopes, T, Fuster-Tormo, F, Montesinos, P, Barba, P, Díaz-Beya, M, Hermosín, L, Maluquer, C, González-Campos, J, Bernal, T, Arriaga, MS, Zamora, L, Pratcorona, M, Martino, R, Larrayoz, MJ, Artola, T, Torrent, A, Vall-llovera, F, Tormo, M, Gil, C, Novo, A, Martínez-Sánchez, P, Ribera, J, Queipo, MP, González-Martínez, T, Cabrero, M, Cladera, A, Cervera, J, Orfao, A, Ribera, JM, Genescà, E. Contribution of copy number to improve risk stratification of adult T-cell acute lymphoblastic leukemia patients enrolled in measurable residual disease-oriented trials. HAEMATOLOGICA. 2025; 110(1)DOI:10.3324/haematol.2024.285416. PMID:39113657. IF:10.100(Q1/2D).

Bhambi-Blanco, I, González-Alvarez, N, San-José, P. Alder-Reilly Leukocyte Inclusions in a patient with Mucopolysaccharidosis Type VII. ANNALES DE BIOLOGIE CLINIQUE. 2025; 83(-1)DOI:10.1684/abc.2025.1953. PMID:39953854. IF:0.400(Q4/10D).

de Larrea, CF, Loscertales, J, Cabañas, V, Freiria, C, Blanchard, MJ, Askari, E, Perez, ML, Abril, L, Pardo, JL, Pinzón, S, Gálvez, JD, Amer, N, Páyer, AR, Sánchez, RG, Alcalá, MM, Capote, FJ, Moreno, D, Bolumburu, C, Rubio-Azpeitia, E, Sanz, RG. Observational retrospective study of the treatment of Waldenström's macroglobulinemia with ibrutinib in routine clinical practice in Spain. Therapeutic Advances in Hematology. 2025; 16DOI:10.1177/20406207251379670. PMID:. IF:3.100(Q2/4D).

Döhner, H, Dinardo, CD, Appelbaum, FR, Craddock, C, Dombret, H, Ebert, BL, Fenaux, P, Godley, LA, Hasserjian, RP, Larson, RA, Levine, RL, Miyazaki, Y, Niederwieser, D, Ossenkoppele, G, Röllig, C, Sierra, J, Stein, EM, Tallman, MS, Tien, HF, Wang, JX, Wierzbowska, A, Wei, AH, Löwenberg, B. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. BLOOD. 2024; 144(21)DOI:10.1182/blood.2024025409. PMID:39133932. IF:23.100(Q1/1D).

Salas, MQ, Cascos, E, López-García, A, Pérez, E, Baile-González, M, Rodríguez, CM, Cascón, MJP, Luque, M, Esquirol, A, Fernando, IH, Peña-Muñóz, F, Ormtegi, IO, Marín, AJS, Fernández-Luis, S, Dominguez-García, JJ, Fernández, SV, Girón, MFD, Pinedo, LG, Garcia, L, González-Rodriguez, AP, Torrado, T, Filaferro, S, Cedillo, A, Orti, G, Chacón, MJ. Cardiac events after allo-HCT in patients with acute myeloid leukemia. Blood Advances. 2024; 8(21)DOI:10.1182/bloodadvances.2024013535. PMID:39178345. IF:7.100(Q1/2D).